Market Place
Sourcing Support
Merck signs up to $3.3 billion cancer drug deal with LaNova
16 Nov 2024 //
REUTERS
Summit Therapeutics Reports Q3 2024 Progress & Financial Results
30 Oct 2024 //
BUSINESSWIRE
Summit Therapeutics Q3 2024 Results & Operational Progress Call
23 Oct 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Rule
04 Oct 2024 //
BUSINESSWIRE
Summit Completes HARMONi Trial Enrollment For NSCLC Treatment
03 Oct 2024 //
BUSINESSWIRE
Ivonescimab Combo Shows Promise In CRC, TNBC, HNSCC at ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
PESG Reports On Nuvectis Pharma`s NXP900
16 Sep 2024 //
BUSINESSWIRE
Summit Therapeutics Raises $235 Million
12 Sep 2024 //
BUSINESSWIRE
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Ivonescimab Outperforms Pembrolizumab In First-Line PD-L1+ NSCLC
08 Sep 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
BUSINESSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
Summit Therapeutics Reports Inducement Grants
09 Aug 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Q2 2024 Financial Results And Progress
06 Aug 2024 //
BUSINESSWIRE
Summit Therapeutics To Host Q2 2024 Results Call On August 6
29 Jul 2024 //
BUSINESSWIRE
Summit And MD Anderson Partner On Ivonescimab Development
25 Jul 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
03 Jul 2024 //
BUSINESSWIRE
Summit Appoints Jeff Huber, Transformational Google and GRAIL Executive
27 Jun 2024 //
BUSINESSWIRE
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
03 Jun 2024 //
BUSINESSWIRE
Ivonescimab HARMONi-A Trial Manuscript Published In JAMA
01 Jun 2024 //
BUSINESSWIRE
Ivonescimab-Chemo Combo Approved In China For EGFRm NSCLC After Chemo
01 Jun 2024 //
BUSINESSWIRE
Summit Reports Inducement Grants Per Nasdaq Rule
30 May 2024 //
BUSINESSWIRE
Summit Cancer Study Triumph Over Keytruda In China
30 May 2024 //
ENDPTS
Summit Therapeutics Q1 2024 Financial Results, Operational Progress
01 May 2024 //
BUSINESSWIRE
Summit Hosts Q1 2024 Call on May 1
24 Apr 2024 //
BUSINESSWIRE
Summit Appoints Dr. Ronaghi To Board
11 Apr 2024 //
BUSINESSWIRE
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
10 Apr 2024 //
BUSINESSWIRE
Illumina CFO Goswami to depart, former Summit exec Dhingra to succeed
09 Apr 2024 //
REUTERS
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC
14 Mar 2024 //
BUSINESSWIRE
Summit to Present at the Barclays 26th Annual Global Healthcare Conference
05 Mar 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Financial Results for the Fourth Quarter
20 Feb 2024 //
BUSINESSWIRE
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Summit to Present at Oppenheimer’s 34th Annual Life Sciences Conference
07 Feb 2024 //
BUSINESSWIRE
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab
08 Jan 2024 //
BUSINESSWIRE
Summit to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Financial Results for the Third Quarter
07 Nov 2023 //
BUSINESSWIRE
Summit Therapeutics to Host Q3 2023 Financial Results
26 Oct 2023 //
BUSINESSWIRE
Summit Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
16 Oct 2023 //
BUSINESSWIRE
Summit Reports Financial Results for Q2 and Six Months Ended June 30, 2023
09 Aug 2023 //
BUSINESSWIRE
Summit Therapeutics to Host Q2 2023 Financial Results on August 9, 2023
02 Aug 2023 //
BUSINESSWIRE
Promising Data for Innovative Bispecific Ivonescimab Featured at ASCO 2023
04 Jun 2023 //
BUSINESSWIRE
Ivonescimab Updated Data to be Featured at ASCO 2023
01 Jun 2023 //
BUSINESSWIRE
Summit Therapeutics Reports Financial Results for First Quarter
11 May 2023 //
BUSINESSWIRE
Summit treats first patient in Phase III trial of cancer combo therapy
10 May 2023 //
CLINICAL TRIALS ARENA
Summit Announces Initial Indications for Trials for Ivonescimab (SMT112)
03 May 2023 //
BUSINESSWIRE
Summit Therapeutics Reports Financial Results for the Fourth Quarter
09 Mar 2023 //
BUSINESSWIRE
Summit closes $500M raise, despite lower market cap; Revolution raises $300M
03 Mar 2023 //
ENDPTS
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
03 Mar 2023 //
BUSINESSWIRE
Summit Therapeutics’ Rights Offering Nearing Expiration Date
23 Feb 2023 //
BUSINESSWIRE
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
30 Jan 2023 //
BUSINESSWIRE
Summit Closes Deal with Akeso to In-License Innovative Bispecific Antibody
20 Jan 2023 //
BUSINESSWIRE
Summit Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
BUSINESSWIRE
Summit bets $5B that Akeso’s bispecific will reach cancer peak
07 Dec 2022 //
FIERCEBIOTECH
Bouncing from major setback, Summit hands out $500M cash for cancer drug
06 Dec 2022 //
ENDPTS
Summit Therapeutics Appoints Alessandra Cesano to its Board of Directors
17 Nov 2022 //
GLOBENEWSWIRE
Summit Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its BOD
17 Nov 2022 //
GLOBENEWSWIRE
Summit Therapeutics Reports Financial Results and Operational Progressfor the 3Q
09 Nov 2022 //
GLOBENEWSWIRE
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Ridinilazole at IDWeek
20 Oct 2022 //
GLOBENEWSWIRE
Summit to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole
13 Oct 2022 //
GLOBENEWSWIRE
Bob Duggan flies white flag as Summit hunts new owner for clinical-stage effort
04 Oct 2022 //
ENDPTS
